MEMORANDUM & ORDER
Relator Daniel Feldman (“Feldman”) brings this qui tam action on behalf of the United States pursuant to the False Claims Act (“FCA”), 31 U.S.C. § 3729 et seq., claiming that Dr. Wilfred van Gorp (“van Gorp”) and Cornell University Medical College (“Cornell” and, collectively, “Defendants”) submitted false claims to obtain federal research funds administered by the National Institutes of Health (the “NIH”). Defendants move for summary judgment dismissing this action. For the following reasons, Defendants’ mоtion is denied.
BACKGROUND
In April 1997, van Gorp, a professor of psychiatry at Cornell University, applied for a training grant from the NIH. (Defendants’ Local Rule 56.1 Statement of Undis *477 puted Facts dated Jan. 9, 2009 (“56.1 Stmt”) ¶¶ 57, 71; Declaration of Tracey A. Tiska dated Jan. 9, 2009 (“Tiska Deck”) Ex. U: Application for MH19998, Neuropsychology of HIV/AIDS Fellowship (Bates-stamped NIH 000301-000392).) His grant application sought funding for a “Neuropsychоlogy of HIV/AIDS Fellowship” (“Grant Application”). (56.1 Stmt. ¶ 60.) Van Gorp proposed that:
[fjellows will be trained in child and adult clinical and research neuropsychology with a strong emphasis upon research training with HIV/AIDS. Fellows will be assigned a primary mentor/research project and a secondary project during their Fellowship. Fellows’ progress will be monitored by the Training Committeе, which will meet monthly. To mirror the breadth of exposure to a diverse population of HTV infected individuals in Manhattan, we will recruit a diverse applicant pool for our Fellowship, including women and people of traditionally under-represented groups.
(Grant Application at NIH 000302.) Van Gorp also indicated that Fellows would “devote an average of 75% оf their time to research and ... 25% [of their] time to clinical work with ... HIV/AIDS [patients] and other neuropsychiatric disorders.” (Grant Application at NIH 000344.) Van Gorp specified that the majority of the Fellows’ clinical work would be with HIV-positive individuals. (Grant Application at NIH 000344.) Defendants’ Grant Application also detailed a curriculum of “several formal, core didactic cоurses” and a number of electives. (Grant Application at NIH 000345.) Van Gorp identified himself as “Principal Investigator” and thirteen others as “Primary Faculty.” (Grant Application at NIH 000302.) In addition to the Department of Psychiatry at Cornell, van Gorp listed the Center for Special Studies at New York Hospital (N.Y.H)Cornell Medical Center, Gay Men’s Health Crisis, Memorial Sloan Kettering Cancer Cеnter, and St. Vincent’s Hospital and Medical Center as clinical resources. (Grant Application at NIH 000336.)
The NIH grant review process begins with assignment of a grant application to an Initial Review Group (“IRG”) consisting of twenty independent scientists, who are recognized experts in the field related to the application. (56.1 Stmt. ¶¶ 12, 13, 61.) NIH assigned van Gorp’s Grant Application to an IRG focused exclusively on National Institute of Mental Health (“NIMH”) applications related to HIV/ AIDS. (56.1 Stmt. ¶ 61.)
An IRG’s evaluative process starts with a preliminary review of a grant application by three IRG members. (56.1 Stmt. ¶ 15.) Comments by the three initial reviewers are submitted to the entire IRG. All twenty IRG members then evaluate the application for themselves and score it based on scientific and technical merit. (56.1 Stmt. ¶ 16.) The individual scores from each IRG member are averaged to arrive at a “priority score.” (56.1 Stmt. ¶ 63.)
Van Gorp’s application received a very high priority score of 159. (56.1 Stmt. ¶ 64.) In conjunction with its priority score, the IRG submitted a thirteen-page Summary Statement describing van Gorp’s Grant Application as seeking “establishment of a fellowship training program in the neuropsychology of HIV infection.” (Tiska Deck Ex. V: Summary Statement for Application Number 1 T32 MH19998-01 dated Sept. 15, 1997 (“Summary Statement”) at NIH 000288.) It praised van Gorp and the training faculty as “experienced clinicians and productive researchers,” and characterized them as “an exceptionally strong group of investigators to serve as role models.” (Summary Statement at NIH 000288.) The Summary Statement opined *478 that the Grant Application set out “a well conceived training program, a broad range of ongoing research programs and models, and a diverse clinical population available for study.” (Summary Statement at NIH 000288.)
However, the Summary Statement questioned van Gorp’s focus on HIV/AIDS, noting under a subheading “Overemphasis on Neurоpsychology unrelated to HIV/ AIDS”:
If training in Neuropsychology at CUMC is the cornerstone of these other training programs, and if the proposed training program is to be piggy-backed upon the existing programs (as it appears to be in large measure), the new HIV/AIDS Fellows may get too much clinical work and training in neuropsychology, compared to the desired research training in HIV/AIDS. A final concern is that since the Fellows’ stipends will be supplemented for providing clinical services, their research experiences may be compromised.”
(Summary Statement at NIH 000295.) The Summary Statement also recommended limiting funding to two fellows, not three as requested by Defendants, because there were only two neuropsychologists among the сore faculty. (56.1 Stmt. ¶ 65; Summary Statement at NIH 000289.)
Based on the Summary Statement’s recommendation, NIMH approved funding for two fellows and recommended support for an additional four years. (56.1 Stmt. ¶ 69; Tiska Decl. Ex. Y: Notice of Grant Award dated Sept 30, 1997 (“Notice of Grant”) at NIH 000198-99.) The Notice of Grant stated that funding was conditioned on the “application submitted to, and as approved by, the [Public Health Service] on the above titled project and is subject to the terms and conditions incorporated either directly or by referenc[e]” in the applicable grant program legislation and regulations. (Award Notice at NIH 000198.) The Notice of Grant did not specify any additional restrictions or protocols to implement the fellowship. (Notice оf Grant at NIH 000198.)
After the Fellowship program commenced, one of the primary sources of HIV-positive research subjects contemplated by the Grant Application' — Dr. Judith Rabkin’s cohort — became unavailable. (56.1 Stmt. ¶¶ 140-41.) Van Gorp attempted to compensate for loss of the Rabkin cohort by securing additional research grants for HIV-positive subjects and identifying a cohort of older, HIV-positive adults at UCLA. (56.1 Stmt. ¶¶ 97,142-44.)
After initial funding, Cornell and van Gorp submitted renewal applications for continued funding for subsequent years. (56.1 Stmt. ¶ 86.) Each renewal application required a progress report describing the Fellows’ activities for the preceding twelve-month period. (56.1 Stmt. ¶ 87; Tiska Decl. Ex. PP: Application for Continuing Grant dated Jan. 21, 1998; Tiska Decl. Ex. QQ: Application for Continuing Grant dated Jan. 21, 1999; Tiska Decl. Ex. RR: Application for Continuing Grant dated Feb. 7, 2000; Tiska Decl. Ex. SS: Application for Continuing Grant dated Jan. 30, 2001.) NIMH instructions require that progress reports “[hjighlight progress in implementation and developments or changes that have occurred” and “[n]ote any difficulties encountered by the program.” (Tiska Decl. Ex. M: Additional Instruction for Preparing a Continuatiоn Application for an Institutional National Research Award Grant (“Additional Instructions”) at V-2.)
DISCUSSION
I. Legal Standard
Summary judgment is appropriate “if the pleadings, the discovery and disclosure
*479
materials on file, and any affidavits show that there is no genuine issue as to any material fact and that the movant is entitled to judgment as a matter of law.” Fed.R.Civ.P. 56(c);
see also Anderson v. Liberty Lobby, Inc.,
To impose liability under the False Claims Act generally, a relator must show that a defendant (1) made a claim, (2) to the United States government, (3) that is false or fraudulent, (4) knowing of its falsity, and (5) seeking payment from the federal treasury.
Mikes v. Straus,
II. “False or Fraudulent”
The FCA does not define the term “false or fraudulent.” However, “the juxtaposition of the word ‘false’ with the word ‘fraudulent,’ plus the meanings of the words comprising the phrase ‘false claim,’ suggest an improper claim is aimed at extracting money the government otherwise would not have paid.”
Mikes,
Feldman contends that Cornell and van Gorp made false statements in both the Grant Application and the Progress Reports. There are material issues of fact which preclude a grant of summary judgment to Cornell and van Gorp. They include, inter alia. (1) whether the curriculum described in the Grant Application was adequately covered — the Grant Application described specific didactic courses but Feldman contends certain subjects like the Neuropsychology of HIV-1 infection were not even discussed (Rel. Ex. G: Deposition of Dr. Elizabeth Ryan, Jan. 24, 2008 (“Ryan Dep.”) at 227:13-229:9); (2) whether the allocation between research and clinical work was accurately described in the Grant Application and progress reports — Feldman offers testimony by former Fellows that clinical work occupied significantly more than 25% of their time (See Ryan Dep. at 246-47; Rel. Ex. E: Deposition of Kimberly Louis dated Sept. 9, 2008 at 40-42); (3) whether it is material that, contrary to the Grant Application, a majority of the patients seen by the Fellows in their clinical work were not HIV-positive; (4) whether the Grant Application accurаtely disclosed additional clinical resources — such as the Gay Men’s Health Crisis which was never contacted by van Gorp; and (5) whether it is material that the Progress Reports did not mention programmatic changes such as loss of the Rabkin cohort, absence of formal coursework, or fewer-than-expected HIV-positive patients available for clinicаl work. (Tiska Decl. Ex. PP: Application for Continuing Grant dated Jan, 21, 1998; Tiska *480 Decl. Ex. QQ: Application for Continuing Grant dated Jan. 21, 1999; Tiska Decl. Ex. RR: Application for Continuing Grant dated Feb. 7, 2000; Tiska Decl. Ex. SS: Application for Continuing Grant dated Jan. 30, 2001 (collectively “Progress Reports”).)
III. Materiality
While the Second Circuit has declined to decide whether materiality is an element for a claim under the False Claims Aсt,
Mikes,
Six of seven circuits finding a materiality element for a False Claims Act claim have adopted the “natural tendency” test. This test “focuses on the potential effect of the false statement when it is made rather than on the false statement’s actual effect after it is discovered.”
United States ex rel. Antidiscrimination Ctr. оf Metro New York, Inc. v. Westchester Cty. N.Y.,
668 F.Supp.2d. 548, 569,
There is no dispute that the fellowship program as implemented differed from the program described in the Grant Application. (Compare Grant Application at NIH 000344-352, with 56.1 Stmt. ¶97^)-&).) The question is whether those differences are material.
Defendants offer affidavits from three IRG members that they would not have scored the Grant Application any differently even if all of Feldman’s allegations were true. (56.1 Stmt. ¶ 66; Tiska Decl. Ex. J: Declaration of Dr. Marlene Oscar Berman dated Jan. 5, 2009, at ¶ 16, 18-22; Tiska Decl. Ex K: Declaration of Dr. Robert A. Bornstein dated Dec. 30, 2008, at ¶¶ 14 20, 24, 25, 27, 29; Tiska Dеcl. Ex. W: Declaration of Dr. William Joseph Woods dated Jan. 8, 2009 at ¶¶ 3-4). Defendants also rely on another IRG member, who testified that the most important factor for him was van Gorp’s record of accomplishment. (56.1 Stmt. ¶ 67; Tiska Dec’l. Ex. X: Declaration of Dr. Geoffrey T. Fong dated Jan. 8, 2009, at ¶¶ 6-7.)
Feldman counters that the Summary Statement itself demonstrates the materiality of the alleged false statements. Specifically, the Summary Statement questioned the “[o]veremphasis on [n]europsychology unrelated to HIV/AIDS” and noted that the new HIV/AIDS Fellows may get “too much clinical work and training in neuropsychology, compared to the desired research training in HIV/ *481 AIDS.” (Summary Statement at NIH 000295.)
Additionally, the IRG Summary Statement specifically identifies other aspects of the Grant Applicatiоn as strengths that Feldman has alleged were false — namely the 75/25 percentage split between research and clinical work (Summary Statement at NIH 000291), and the “diverse clinical population available for study.” (Summary Statement at NIH 000288.) This clearly creates a disputed issue of material fact that the testimony of four of the twenty members of the IRG does not obviate.
IV. Scienter
“The [Fаlse Claims] Act defines ‘knowingly’ as either: (1) possessing actual knowledge; (2) acting in deliberate ignorance of falsity; or (3) acting in reckless disregard of falsity.”
Mikes,
While Feldman has adduced evidence that many of the differences between the progrаm described in the Grant Application and the program in practice were not disclosed in the Progress Reports, Defendants contend that this cannot support a finding of scienter because van Gorp relied on his reasonable interpretation of the NIH reporting guidelines. But the question is not one of interpretation. The plain language of the instructions for completing the Progress Reports requires that the applicant “[n]ote any difficulties encountered by the program.” (Additional Instructions, at V-2.) Whether any of the differences between the Grant Application and the program in practice were “difficulties” is a fact question.
Feldman asserts that van Gorp hired several Fellows who were not primarily interested in HIV/AIDS, despite the fact the Grant Application was focused on Neuropsychology of HIV/AIDS. Moreover, the Grant Application provided that Fellows would spend a majority of their clinical time with HIV-positive patients. Van Gorp posits that this goal could not be achieved because of the unanticipated success of HIV/AIDS drugs. Yet the Grant Application exрlicitly recognized the impact of these drugs on the population of HIV-positive individuals.
While the evidence supporting a finding of scienter is relatively tenuous, the question is closely tied to the ultimate factual issues. Indeed, the Court of Appeals has been “lenient in allowing scienter issues to withstand summary judgment based on fairly tenuous inferences,” because such issues are “appropriate for resolution by the trier of fact.”
In re DDAVP Direct Antitrust Litig.,
V. Damage to the Government
The Second Circuit has declined to decide whether damage to the United States was a required element of the FCA, noting that there is a split of authority on the issue.
Mikes,
VI. Original Source
In order for a court to have subject matter jurisdiction over an FCA claim, the claim must be brought by an “original source.” 31 U.S.C. § 3730(e)(4)(B). An “original source” under the FCA is one who (1) “has direct and independent knowledge of the information on which the allegations are based,” (2) “has voluntarily provided the information to the Government before filing an action under this section” and (3) has “directly or indirectly been a source to the entity that publicly disclosed the allegations on which the suit is based.” 31 U.S.C. § 3730(e)(4)(B);
United States v. N.Y. Med. Coll.,
“Although a relator need not possess all relevant information in order to have ‘independent’ knowledge, he or she must possess ‘substantive information about the particular fraud, rather than merely backgrоund information which enables a putative relator to understand the significance of a publicly disclosed transaction or allegation.’ ”
United States ex rel. Smith v. Yale Univ.,
The public disclosure requirement was “designed to preclude
qui tarn
suits based on information that would have been equally available to strangers to the fraud transaction had they chosen to look for it as it was to the relator. Information gleaned in litigation and on file in the clerk’s office falls in this category.”
Kreindler,
CONCLUSION
For the foregoing reasons, Defendants’ motion for summary judgment is denied. The parties are directed to appear for a *483 conference on December 21, 2009 at 11:00 a.m.
SO ORDERED:
Notes
. Congress amended the False Claims Act, effective May 20, 2009, to explicitly include materiality as an element of a claim. While the amendment applies to conduct that occurs on or after the date of enactment, Congress’s decision to include materiality buttresses those decisions reading a materiality element into the statute’s earlier iteration.
